These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 24675233)

  • 1. Renal cell carcinoma: molecular biology and targeted therapy.
    Su D; Stamatakis L; Singer EA; Srinivasan R
    Curr Opin Oncol; 2014 May; 26(3):321-7. PubMed ID: 24675233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapeutic strategies for the management of renal cell carcinoma.
    Singer EA; Gupta GN; Srinivasan R
    Curr Opin Oncol; 2012 May; 24(3):284-90. PubMed ID: 22343386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
    Su D; Singer EA; Srinivasan R
    Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successes and limitations of targeted therapies in renal cell carcinoma.
    Pracht M; Berthold D
    Prog Tumor Res; 2014; 41():98-112. PubMed ID: 24727990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal management of metastatic renal cell carcinoma: current status.
    Escudier B; Albiges L; Sonpavde G
    Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapeutics in refractory renal cell carcinoma.
    Koshkin VS; Rini BI
    Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy.
    Bedke J; Gouttefangeas C; Singh-Jasuja H; Stevanović S; Behnes CL; Stenzl A
    World J Urol; 2014 Feb; 32(1):31-8. PubMed ID: 23404195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
    Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
    Costa LJ; Drabkin HA
    Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on targeted therapies for clear cell renal cell carcinoma.
    Singer EA; Gupta GN; Srinivasan R
    Curr Opin Oncol; 2011 May; 23(3):283-9. PubMed ID: 21330923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic renal cell carcinoma: many treatment options, one patient.
    Rini BI
    J Clin Oncol; 2009 Jul; 27(19):3225-34. PubMed ID: 19470934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of available treatment options for renal cell carcinoma.
    Derosa L; Albiges L; Massard C; Loriot Y; Fizazi K; Escudier B
    Expert Opin Drug Saf; 2016 Aug; 15(8):1097-106. PubMed ID: 27142582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
    Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
    Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy.
    Diamond E; Molina AM; Carbonaro M; Akhtar NH; Giannakakou P; Tagawa ST; Nanus DM
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):518-26. PubMed ID: 26321263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatment of renal cell cancer: A comprehensive review.
    Sánchez-Gastaldo A; Kempf E; González Del Alba A; Duran I
    Cancer Treat Rev; 2017 Nov; 60():77-89. PubMed ID: 28898679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
    Hutson TE
    Oncologist; 2011; 16 Suppl 2(Suppl 2):14-22. PubMed ID: 21346036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New agents and new targets for renal cell carcinoma.
    Philips GK; Atkins MB
    Am Soc Clin Oncol Educ Book; 2014; ():e222-7. PubMed ID: 24857106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland.
    Sandmeier N; Rothschild SI; Rothermundt C; Cathomas R; Schardt J; Berthold D; von Burg P; Müller B; Beyer J; Vogt DR; Stenner F
    Clin Genitourin Cancer; 2018 Aug; 16(4):e711-e718. PubMed ID: 29503245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.